Preventative tools of the future: Predicting the individual risk of cytomegalovirus infection after transplant

Transplantation

Volumn 93, Issue 5, 2012, Pages 467-468

  Kotton, Camille N ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CYTOMEGALOVIRUS VACCINE;

ADOPTIVE TRANSFER; ANTIVIRAL THERAPY; CELLULAR IMMUNITY; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSPOT ASSAY; GRAFT RECIPIENT; HIGH RISK PATIENT; HUMAN; INFECTION PREVENTION; INFECTION RISK; KIDNEY TRANSPLANTATION; MINOR HISTOCOMPATIBILITY COMPLEX; NOTE; PATIENT MONITORING; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; RISK REDUCTION;

CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNITY, CELLULAR; MALE; MONITORING, IMMUNOLOGIC; T-LYMPHOCYTES;

EID: 84857656513     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318242165d     Document Type: Note

References (7)

1. Freeman RB Jr. The 'indirect' effects of cytomegalovirus infection. Am J Transplant 2009;9:2453.
2. Ljungman P, Hakki M, Boeckh M. Cytomegalovirus in hematopoietic stem cell transplant recipients. Infect Dis Clin North Am 2010;24:319.
3. Kotton CN, Kumar D, Caliendo AM, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010;89:779.
4. Abate D, Saldan A, Fiscon M, et al. Evaluation of cytomegalovirus (CMV)-specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis, or preemptive therapy but not antithymocyte globulin treatment contribute to CMV-specific T cell reconstitution in kidney transplant recipients. J Infect Dis 2010;202:585.
5. Abate D, Cesaro S, Cofano S, et al. Diagnostic utility of human cytomegalovirus-specific T-cell response monitoring in predicting viremia in pediatric allogeneic stem cell transplant patients. Transplantation 2012;93:536.
6. Borchers S, Luther S, Lips U, et al. Tetramer monitoring to assess risk factors for recurrent cytomegalovirus reactivation and reconstitution of antiviral immunity post allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2011;13:222.
7. Krol L, Stuchly J, Hubacek P, et al. Signature profiles of CMV-specific T-cells in patients with CMV reactivation after hematopoietic SCT. Bone Marrow Transplant 2011;46:1089.